Company Overview: Aytu BioScience

Industry News

5 Apr

Aytu BioScience Presents Latest Clinical Findings for Natesto® at ENDO 2017, the National Endocrine Society’s Annual Scientific Meeting

ENGLEWOOD, Colo., April 4, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it presented two posters demonstrating the safety advantages of Natesto® testosterone nasal gel, including the one-year hematologic safety and tolerability...

Read more

3 Apr

Aytu BioScience Announces Divestiture of Primsol® to Allegis Holdings

ENGLEWOOD, Colo., April 3, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the divestiture of Primsol®, an oral antibiotic solution for urinary tract infections, to Allegis Holdings, LLC. The sale price of...

Read more

14 Mar

Aytu BioScience Announces Peer-Reviewed Publication of Fourth Clinical Study Demonstrating the Utility of MiOXSYS® in the Assessment of Male Infertility

ENGLEWOOD, Colo., March 14, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the publication of a peer-reviewed journal article demonstrating the clinical utility of the Company’s MiOXSYS® System for assessing the level of...

Read more

1 Feb

Aytu BioScience Announces Two Presentations at Endocrine Society 2017 Annual Meeting Highlighting Benefits of Natesto® (Testosterone) Nasal Gel in Men

ENGLEWOOD, Colo., Feb. 1, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that two posters demonstrating clinical data for Natesto® (testosterone) Nasal Gel were accepted for presentation at the Endocrine Society 2017 Annual...

Read more

24 Jan

Aytu BioScience to Present at Noble Capital Markets’ 13th Annual Investor Conference

ENGLEWOOD, Colo., Jan. 24, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that Josh Disbrow, Chairman & Chief Executive Officer, and Jarrett Disbrow, Chief Operating Officer, will present a corporate overview at NobleCon13...

Read more

18 Jan

Aytu BioScience Announces Two Presentations Highlighting Benefits of Natesto® (Testosterone) Nasal Gel in Men at American Urological Association Annual Meeting

ENGLEWOOD, Colo., Jan. 18, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that two posters demonstrating clinical data for Natesto® (testosterone) Nasal Gel were accepted for presentation at the American Urological Association 2017...

Read more

4 Jan

Aytu BioScience to Present at Biotech Showcase 2017 Investor Conference

ENGLEWOOD, Colo., Jan. 4, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that Josh Disbrow, Chairman & Chief Executive Officer, and Jarrett Disbrow, Chief Operating Officer, will present a corporate overview at the...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address